4/A: Amicus Therapeutics Executive Amends SEC Filing to Correctly Report Stock Transactions

Ellen Rosenberg, Chief Legal Officer of Amicus Therapeutics, files an amendment to a previous SEC Form 4 to accurately reflect stock acquisitions and holdings following a performance-based restricted stock unit (PRSU) award and tax withholdings.

Summary

• Ellen Rosenberg, Chief Legal Officer of Amicus Therapeutics, filed an amended SEC Form 4 on March 15, 2024, to correct inaccuracies in a previous filing from January 11, 2024.
• The amendment addresses the omission of shares acquired from the achievement of the 2021 PRSU TSR goal and corrects the reported holdings after shares were withheld for taxes.
• On January 9, 2024, Rosenberg acquired 16,565 shares of common stock at $0.00 due to the PRSU achievement.
• Also on January 9, 2024, 12,000 shares were disposed of at $13.65 per share to cover tax obligations.
• Following these transactions, Rosenberg directly owns 384,219 shares of Amicus Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine correction of an SEC filing. While the initial error is a minor negative, the correction itself is a positive for transparency.

Negatives

• The need for an amended filing indicates an initial error in reporting stock transactions, which could raise concerns about internal controls.

Industry Context

SEC Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, ensuring transparency in the market.

Stakeholder Impact

• The correction of the SEC filing ensures accurate information is available to shareholders and potential investors.

Key Dates